DENTSPLY SIRONA (XRAY) Downgraded by BidaskClub

DENTSPLY SIRONA (NASDAQ:XRAY) was downgraded by equities researchers at BidaskClub from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

Other equities analysts also recently issued reports about the stock. Stephens assumed coverage on shares of DENTSPLY SIRONA in a research note on Tuesday. They issued an “overweight” rating and a $75.00 price target on the stock. HC Wainwright downgraded shares of DENTSPLY SIRONA from a “buy” rating to a “neutral” rating and set a $68.00 price target on the stock. in a research note on Thursday. Stifel Nicolaus restated a “buy” rating on shares of DENTSPLY SIRONA in a research note on Thursday, October 19th. TheStreet downgraded shares of DENTSPLY SIRONA from a “b” rating to a “c+” rating in a research note on Wednesday, August 9th. Finally, Morgan Stanley upped their price target on shares of DENTSPLY SIRONA from $66.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, August 10th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $67.73.

DENTSPLY SIRONA (NASDAQ:XRAY) traded down $0.93 during trading hours on Friday, hitting $66.08. 1,922,536 shares of the company’s stock traded hands, compared to its average volume of 1,911,038. DENTSPLY SIRONA has a 12-month low of $52.53 and a 12-month high of $68.98. The firm has a market capitalization of $15,391.05, a P/E ratio of 26.70, a P/E/G ratio of 2.65 and a beta of 1.31. The company has a debt-to-equity ratio of 0.21, a quick ratio of 1.59 and a current ratio of 2.32.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings data on Friday, November 3rd. The medical instruments supplier reported $0.70 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.66 by $0.04. DENTSPLY SIRONA had a negative net margin of 20.33% and a positive return on equity of 7.56%. The firm had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $978.99 million. During the same period in the previous year, the company earned $0.66 earnings per share. The company’s quarterly revenue was up 5.8% on a year-over-year basis. equities research analysts expect that DENTSPLY SIRONA will post 2.66 earnings per share for the current year.

In other news, insider Mark Thierer acquired 77,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The stock was acquired at an average price of $66.04 per share, with a total value of $5,085,080.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Nicholas W. Alexos acquired 50,000 shares of the business’s stock in a transaction that occurred on Monday, November 13th. The shares were purchased at an average cost of $65.85 per share, with a total value of $3,292,500.00. The disclosure for this purchase can be found here. Corporate insiders own 1.99% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of XRAY. Commonwealth Bank of Australia lifted its holdings in shares of DENTSPLY SIRONA by 19.0% in the second quarter. Commonwealth Bank of Australia now owns 1,626 shares of the medical instruments supplier’s stock worth $104,000 after acquiring an additional 260 shares during the last quarter. Acrospire Investment Management LLC bought a new position in shares of DENTSPLY SIRONA in the second quarter worth about $113,000. Dupont Capital Management Corp bought a new position in shares of DENTSPLY SIRONA in the second quarter worth about $116,000. Massey Quick Simon & CO. LLC bought a new position in shares of DENTSPLY SIRONA in the third quarter worth about $124,000. Finally, Checchi Capital Advisers LLC lifted its holdings in shares of DENTSPLY SIRONA by 2.1% in the second quarter. Checchi Capital Advisers LLC now owns 2,007 shares of the medical instruments supplier’s stock worth $125,000 after acquiring an additional 41 shares during the last quarter. 96.59% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “DENTSPLY SIRONA (XRAY) Downgraded by BidaskClub” was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another publication, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/02/dentsply-sirona-xray-downgraded-by-bidaskclub.html.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply